Topical tranexamic acid in total hip replacement

Completed

• Conditions: Joint arthritis; Musculoskeletal Diseases; Presence of orthopaedic joint implants

• Registration Number: ISRCTN59245192
• Lead Sponsor: niversity Hospital of North Tees and Hartlepool (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-04-24
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 158

Inclusion Criteria

Patients undergoing a primary THR

Exclusion Criteria

1. Allergic to TXA
2. Warfarin or heparin, had a history of haemophilia
3. Deep venous thrombosis, pulmonary embolism
4. Renal impairment
5. Female patients were excluded if they were pregnant

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Blood transfusion rate<br>2. Number of blood units transfused until discharge

Secondary Outcome Measures

Name	Time	Method
1. The visible drain blood loss (first 48 hours)<br>2. Haemoglobin and Haematocrit drops (on day 2 postoperatively)<br>3. General quality of life measure (EUROQOL) preoperative and at 3 months postoperative<br>4. Oxford hip score preoperative and at 3 months postoperative<br>5. Length of stay<br>6. Cost effectiveness analysis